Advanced Analytical markets CE instruments, reagents, and software for nucleic acid analysis while Lasergen is a next-generation sequencing technology developer.
The firm's $80 investment in Lasergen sets the stage for it to develop an integrated sample-to-result clinical genomics workflow by 2020.
Agilent said it will work with Lasergen to build a clinical sequencing workflow based on the smaller firm's Lightning Terminators sequencing chemistry.
LaserGen has named Mimi Healy CEO and to its board of directors. She is taking over from founder Michael Metzker, who developed and patented the company's proprietary Lightning Terminators.
By Julia Karow
By a GenomeWeb staff reporter
By Julia KarowThis article has been updated to include information about Roche/IBM and Genia.
LaserGen has raised $5 million in a Series A financing round, which it will use to demonstrate accurate sequencing of the Escherichia coli genome and to continue developing its next-generation sequencing system.
Last week, the Baylor College of Medicine spinout disclosed that it has teamed up with National Instruments to build and validate a prototype sequencer that uses its "Lightning Terminator" chemistry.
Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.
The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.
Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.